Physician profile
Franklin Galef
NPI 1164439667
$3,118.07
in general payments reported to CMS, 2019-2025
29 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $720 · 2021: $651 · 2022: $498 · 2023: $56.72 · 2024: $136 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $862.52 | 2019-2022 | |
| Pfizer INC. | $602.40 | 2019-2022 | |
| Glaxosmithkline, LLC. | $349.66 | 2020-2025 | Trelegy Ellipta |
| Boston Scientific Corporation | $219.06 | 2023-2025 | Watchman Flx, Watchman |
| Janssen Pharmaceuticals, INC | $174.44 | 2019-2021 | |
| Novo Nordisk INC | $109.70 | 2019-2022 | |
| Eisai INC. | $89.43 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $69.06 | 2019-2021 | |
| Mannkind Corporation | $62.82 | 2019-2022 | |
| Antares Pharma, INC. | $56.37 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.08 | 2022 | |
| Amgen INC. | $44.92 | 2019 | |
| Amarin Pharma, INC. | $41.35 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $40.14 | 2019-2021 | |
| Aytu Biopharma, INC. | $39.05 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $34.40 | 2022 | |
| Organon LLC | $33.58 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $30.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.46 | 2022 | |
| Philips North America LLC | $23.97 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.32 | 2022 | |
| Electromed, INC. | $18.69 | 2022 | |
| Radius Health, INC. | $17.93 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.41 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $16.18 | 2022 | |
| Mylan Specialty L.P. | $15.08 | 2019 | |
| Lilly USA, LLC | $13.08 | 2019 | |
| Astellas Pharma US INC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franklin Galef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.